Zydus Lifesciences rose 2.15% to Rs 1,033.80 after its subsidiary, Zydus Lifesciences Global FZE, has entered into an exclusive licensing & supply agreement with Synthon BV for Ozanimod capsules, the generic version of Zeposia, in the US market.

Synthon has filed an abbreviated new drug application (ANDA) with the US Food and Drug Administration (FDA) seeking approval for Ozanimod capsules, indicated for the treatment of relapsing forms of multiple sclerosis.

The company has already received tentative FDA approval within 30 months of filing, positioning the product for a shared 180-day exclusivity period upon launch.

Under the agreement, Synthon will be responsible for securing final regulatory approval, as well as the manufacturing and supply of the product. Zydus will take charge of commercialisation in the US market.

Zeposia (Ozanimod) is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. It is also approved for moderately to severely active ulcerative colitis (UC) in adults. Zeposia is a trademark of Receptos, LLC, a Bristol Myers Squibb company.

Also Read

Glenmark Pharma up 3% on DCGI nod to start phase 3 trial of Envafolimab

ITC shares drop 2% amid GST tweaks; Analysts decode impact, stock strategy

Anti-immigration protests in Australia: Indians power economy, not flood it

Stock Market LIVE: Nifty, Sensex reverse early gains; FMCG, IT top losers; Rupee hits record low

Apple's India sales hit record $9 billion on high demand, big retail push

Speaking on the development, president and chief executive officer of Zydus Pharmaceuticals (USA) Inc., Punit Patel said, "This collaboration with Synthon enables us to bring this important treatment to the U.S. market. This collaboration reinforces our strategic focus on advancing care in therapeutic areas and reflects our commitment to making essential medicines more accessible to patients.

Anish Mehta, chief executive officer, Synthon BV, commented This collaboration with Zydus for Ozanimod capsules continues to underscore our proven expertise in developing first-tomarket, complex generic products. We are pleased to strengthen our partnership with Zydus as we continue advancing our strategic commitment to expanding access to essential medicines.

The total addressable market for Ozanimod capsules in the U.S. is estimated at approximately US$637 million, according to IQVIA MAT data from July 2025.

Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.

The companys consolidated net profit rose 3.3% to Rs 1,466.80 crore on 7% rise in revenue from operations to Rs 6,467 crore in Q1 FY26 over Q1 FY25.

Powered by Capital Market - Live News

More From This Section

Volumes spurt at SKF India Ltd counter

Divgi TorqTransfer Systems fixes record date for final dividend

Barometers pare gains; Nifty below 24,750; auto shares gear up

Indian Rupee off to tepid start, stays above 88 per US dollar mark

Gift Nifty signals strong opening amid new GST reforms